Welcome to AstraZeneca United States
Beginning its journey in 1953, AstraZeneca became one of the first pharmaceutical companies operating in the United States
Latest News from AstraZeneca United States
FASLODEX® (fulvestrant) receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib
FASLODEX in combination with abemaciclib showed 16.4 months of progression-free survival (PFS)
Second approval in three months expands treatment options for women with HR+, HER2- advanced breast cancer
FASENRA (benralizumab) receives US FDA approval for severe eosinophilic asthma
FASENRA distinctively targets and rapidly depletes eosinophils and is the first respiratory biologic with an 8-week maintenance dosing schedule
FDA approval based on Phase III program demonstrating up to 51% reduction in asthma exacerbations, significant improvement in lung function and a 75% reduction in daily oral steroid use
AstraZeneca shares scientific updates from its extensive cardiovascular, renal and metabolic diseases (CVMD) portfolio at AHA 2017
AstraZeneca and MedImmune, its global biologics research and development arm, will be underlining its scientific focus on cardiovascular, renal and metabolic diseases (CVMD) with 28 presentations, including two late-breaking trials, at the American Heart Association (AHA) Scientific Sessions, November 11-15, 2017 in Anaheim, California.
US FDA approves AstraZeneca’s CALQUENCE ® (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma
Accelerated approval of Bruton tyrosine kinase (BTK) inhibitor in MCL marks AstraZeneca’s entry into the treatment of blood cancers
80% of patients receiving CALQUENCE achieved an overall response, with 40% achieving a complete response
Latest AZ&You Blog Articles
If you are passionate about science, these stories will show you how the latest and most exciting projects we have been working on and the people behind them.